Vioxx Gains Six Months Pediatric Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck gains six months of pediatric exclusivity for its COX-2 inhibitor Vioxx (rofecoxib) with a supplemental NDA filing for juvenile rheumatoid arthritis, the company announced Feb. 27